Is digitalis a therapy for breast carcinoma?

Area of Science:

• Oncology
• Pharmacology
• Cardiology

Background:

• Previous studies indicated digitalis affects breast carcinoma cytometric features and recurrence.
• Current research focuses on the anti-proliferative and apoptosis-inducing effects of digitalis glycosides on cancer cells.
• Digitalis, a cardiac glycoside, has a long history of medicinal use.

Purpose of the Study:

• To conduct a long-term follow-up study on breast carcinoma patients treated with digitalis.
• To evaluate the impact of digitalis on mortality rates and tumor characteristics in breast cancer patients.
• To explore the potential of digitalis derivatives in cancer drug development.

Main Methods:

• Long-term follow-up (22.3 years) of 175 breast carcinoma patients.
• Comparison of outcomes between 32 patients on digitalis treatment and those not on digitalis.
• Analysis of death rates, tumor proliferation, and aneuploidy.

Main Results:

• A significantly lower death rate from breast carcinoma in patients on digitalis (6%) compared to those not on digitalis (34%).
• Reduced tumor proliferation and aneuploidy observed in patients treated with digitalis.
• Statistical significance was noted, though limited by a low number of deaths in the digitalis group.

Conclusions:

• Digitalis derivatives warrant serious consideration for cancer drug design due to observed effects on cancer cells.
• The potential of digitalis in cancer therapy may surpass current adjuvant treatments in efficacy and side-effect profiles.
• Further research into digitalis's role in oncology is crucial and holds significant promise.